Establishment of a noninvasive predictive model for antiviral therapy in patients with chronic hepatitis B virus infection and an age of ≤30 years

Changxiang LAI; Qingrong TANG; Xiulian ZHANG; Qiyuan TANG; Zhiyu LI; Xuan ZHOU; Wenjie XIAN; Ruikun CHEN; Xiaojuan WU; Fang WANG

doi:10.12449/JCH240708

Volume 40 Issue 7

Jul. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(7): 1328-1333

PDF( 905 KB)

Establishment of a noninvasive predictive model for antiviral therapy in patients with chronic hepatitis B virus infection and an age of ≤30 years

DOI: 10.12449/JCH240708

1.
Department of Liver Diseases，National Clinical Research Center for Infectious Disease，Shenzhen Third People’s Hospital，The Second Affiliated Hospital of Southern University of Science and Technology，Shenzhen，Guangdong 518116，China
2.
Department of Infectious Diseases，The First Hospital of Changsha，Changsha 410000，China

Research funding:

Shenzhen Key Medical Discipline Construction Fund (SZXK076)

More Information

Corresponding author: WANG Fang， kaixin919@163.com （ORCID： 0009-0003-0092-3403）
Received Date: 2023-11-08
Accepted Date: 2024-01-17
Published Date: 2024-07-25

Abstract

Abstract

Objective To predict whether antiviral therapy is required in patients with chronic hepatitis B virus （HBV） infection and an age of ≤30 years by establishing a noninvasive model， and to investigate the diagnostic value of this model. Methods A retrospective analysis was performed for the clinical data of 175 patients with chronic HBV infection who were admitted to Shenzhen Third People’s Hospital from January 2017 to January 2023 and met the inclusion criteria， and according to the results of liver biopsy， they were divided into treatment group with 41 patients （with indications for antiviral therapy） and observation group with 134 patients （without indications for antiviral therapy）. The two groups were analyzed in terms of the indicators including clinical data， imaging examinations， and serum biochemical parameters. The univariate and multivariate Logistic regression analyses were used to investigate the parameters affecting the indication for antiviral therapy， and different models for predicting the need for antiviral therapy were constructed based on related parameters. The receiver operating characteristic （ROC） curve was used to compare the diagnostic value of different models. The independent-samples t test was used for comparison of normally distributed continuous variables between groups， and the Mann-Whitney U rank sum test was used for comparison of non-normally distributed continuous variables between groups； the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. Results There were significant differences between the treatment group and the observation group in alanine aminotransferase， ferritin， total cholesterol （CHOL）， triglyceride， platelet count， liver stiffness measured by sound touch elastography （STE）， and procollagen III N-terminal propeptide （PIIIP）（all P<0.05）. The multivariate Logistic regression analysis showed that CHOL （odds ratio ［OR］=0.4， 95% confidence interval ［CI］： 0.2‍ ‍—‍ ‍1.0）， STE （OR=1.5， 95%CI： 1.0‍ ‍—‍ ‍2.1）， and PIIIP （OR=1.1， 95%CI： 1.0‍ ‍—‍ ‍1.1） were independent predictive factors for the indications for antiviral therapy. Model 1 （STE+PIIIP+CHOL）， model 2 （STE+PIIIP）， model 3 （STE+CHOL）， model 4 （PIIIP+CHOL） had an area under the ROC curve of 0.908， 0.848， 0.725， and 0.725， respectively， while STE， PIIIP， and CHOL used alone had an AUC of 0.836， 0.725， and 0.634， respectively， suggesting that model 1 had the largest AUC， with a specificity of 77.34% and a sensitivity of 96.36%， and had a significant difference compared with STE， PIIIP， CHOL， and the models 2， 3， and 4 （Z=0.21， 3.08， 3.06， 3.23， 0.89， and 0.88， all P<0.05）. Conclusion The noninvasive model established based on CHOL， STE， and PIIIP has a good value in predicting the need for antiviral therapy in patients with chronic HBV infection and an age of ≤30 years.
- Hepatitis B virus,
- Forecasting,
- Age Distribution

FullText(HTML)

References(16)

References

[1]	World Health Organization. Global hepatitis report, 2017[EB/OL].( 2019-04-04)[ 2022-07-05]. https://www.who.int/hepatitis/publications/global hepatitis report2017/en/. https://www.who.int/hepatitis/publications/global hepatitis report2017/en/
[2]	LIU J, LIANG WN, JING WZ, et al. Countdown to 2030: Eliminating hepatitis B disease, China[J]. Bull World Health Organ, 2019, 97( 3): 230- 238. DOI: 10.2471/BLT.18.219469.
[3]	FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48( 2): 335- 352. DOI: 10.1016/j.jhep.2007.11.011.
[4]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2022)[J]. Infect Dis Info, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01. 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 传染病信息, 2023, 36( 1): 1- 17. DOI: 10.3969/j.issn.1007-8134.2023.01.01.
[5]	XIAO GQ, YANG JY, YAN LN. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta-analysis[J]. Hepatology, 2015, 61( 1): 292- 302. DOI: 10.1002/hep.27382.
[6]	EKIN N, UCMAK F, EBIK B, et al. GPR, King’s Score and S-Index are superior to other non-invasive fibrosis markers in predicting the liver fibrosis in chronic Hepatitis B patients[J]. Acta Gastroenterol Belg, 2022, 85( 1): 62- 68. DOI: 10.51821/85.1.9156.
[7]	LIANG XE, DAI L, YANG SL, et al. Combining routine markers improves the accuracy of transient elastography for hepatitis B cirrhosis detection[J]. Dig Liver Dis, 2016, 48( 5): 512- 518. DOI: 10.1016/j.dld.2016.02.002.
[8]	ZHOU XL, MA X, WANG YB, et al. Value of aspartate aminotransferase-to-platelet ratio index, fibrosis-4, and gamma-glutamyl transpeptidase-to-platelet ratio in diagnosis of liver inflammation grade in patients with chronic hepatitis B[J]. J Clin Hepatol, 2021, 37( 9): 2066- 2070. DOI: 10.3969/j.issn.1001-5256.2021.09.013. 周新兰, 马鑫, 王雁冰, 等. APRI、FIB-4和GPR对慢性乙型肝炎肝脏炎症程度的诊断价值[J]. 临床肝胆病杂志, 2021, 37( 9): 2066- 2070. DOI: 10.3969/j.issn.1001-5256.2021.09.013.
[9]	GUHA IN, ROSENBERG WM. Noninvasive assessment of liver fibrosis: Serum markers, imaging, and other modalities[J]. Clin Liver Dis, 2008, 12( 4): 883- 900, x. DOI: 10.1016/j.cld.2008.07.010.
[10]	ZACCHERINI G, BERNARDI M. The role and indications of albumin in advanced liver disease[J]. Acta Gastroenterol Belg, 2019, 82( 2): 301- 308.
[11]	LIN WQ, SUN XC, FENG T, et al. Application of serum cholinesterase albumin total cholesterol level in liver function evaluation of patients with hepatitis cirrhosis[J]. J Pract Med Tech, 2020, 27( 4): 459- 461. DOI: 10.19522/j.cnki.1671-5098.2020.04.021. 林伟强, 孙小纯, 冯涛, 等. 血清胆碱酯酶白蛋白总胆固醇水平检测在肝炎肝硬化患者肝功能评估中的应用[J]. 实用医技杂志, 2020, 27( 4): 459- 461. DOI: 10.19522/j.cnki.1671-5098.2020.04.021.
[12]	ZHANG LJ, SHU XC, XIAO YH. Clinical significance of serum total cholesterol, albumin, prealbum and total bile acid determination in paitients with liver cirrhosis[J]. China Pract Med, 2010, 5( 15): 15- 16. DOI: 10.14163/j.cnki.11-5547/r.2010.15.095. 张丽娟, 舒晓春, 肖艳辉. 血清TC、ALB、PA和TBA测定在肝硬化中的临床意义[J]. 中国实用医药, 2010, 5( 15): 15- 16. DOI: 10.14163/j.cnki.11-5547/r.2010.15.095.
[13]	MA LJ, JI D, WANG CY, et al. A noninvasive diagnosis model for chronic hepatitis B patient based on conventional parameters[J]. Med J Chin People’s Liberation Army, 2019, 44( 10): 857- 861. DOI: 10.11855/j.issn.0577-7402.2019.10.08. 马丽君, 纪冬, 王春艳, 等. 基于常规指标建立肝脏炎症及纤维化无创诊断模型[J]. 解放军医学杂志, 2019, 44( 10): 857- 861. DOI: 10.11855/j.issn.0577-7402.2019.10.08.
[14]	YANG K, PAN Y, JIN L. Clinical value on serum sCD14 level in predicting liver inflammation and fibrosis grade in patients with chronic hepatitis B[J]. J Jiujiang Univ Nat Sci Ed, 2021, 36( 3): 85- 89. DOI: 10.19717/j.cnki.jjun.2021.03.022. 杨凯, 潘颖, 金蕾. 慢性乙型肝炎患者血清sCD14分子预测肝脏炎症和纤维化等级的临床价值[J]. 九江学院学报(自然科学版), 2021, 36( 3): 85- 89. DOI: 10.19717/j.cnki.jjun.2021.03.022.
[15]	ZHU L, YANG JR, HE LL, et al. Advances on the application of transient elastography in the diagnosis of liver fibrosis[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 3): 16- 22. DOI: 10.3969/j.issn.1674-7380.2023.03.003. 朱璐, 杨君茹, 何玲玲, 等. 瞬时弹性成像在肝纤维化诊断中的应用研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 3): 16- 22. DOI: 10.3969/j.issn.1674-7380.2023.03.003.
[16]	ZHENG M, CAI WM, WENG HL, et al. ROC curve in evaluation of serum fibrosis index for diagnosing hepatic fibrosis[J]. Chin J Infect Dis, 2002, 20( 4): 225- 228. DOI: 10.3760/j.issn: 1000-6680.2002.04.009. 郑敏, 蔡卫民, 翁红雷, 等. ROC曲线评价血清纤维化指标对诊断肝纤维化的价值[J]. 中华传染病杂志, 2002, 20( 4): 225- 228. DOI: 10.3760/j.issn:1000-6680.2002.04.009.

Relative Articles

[1]	Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association， Chinese Society of Liver Cancer， Liver Study Group of Surgery Committee of Beijing Medical Association， et al. Expert consensus on the sequential surgery following conversion therapy based on the combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)[J]. Journal of Clinical Hepatology, 2025, 41(1): 30-40. doi: 10.3760/cma.j.cn113884-20240814-00245
[2]	Shichun LU. Challenges and reflections on conversion therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(9): 1738-1740. doi: 10.12449/JCH240904
[3]	Youcheng XIE, Shun CHEN, Chuyi LI, Ying ZHENG, Dong JIA, Jiucong ZHANG, Xiaohui YU. Application of immune checkpoint inhibitors in liver transplantation for patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 941-947. doi: 10.3969/j.issn.1001-5256.2023.04.030
[4]	Shun CHEN, Youcheng XIE, Junke WANG, Baoyin ZHAO, Jiucong ZHANG, Pan WANG, Xiaohui YU. Association between immune checkpoint inhibitor antitumor therapy and hepatitis B virus reactivation[J]. Journal of Clinical Hepatology, 2023, 39(6): 1424-1430. doi: 10.3969/j.issn.1001-5256.2023.06.027
[5]	Lizhen ZHU, Xiaolei XU, ABUDUSALAMU Aini, Xiaojuan WANG, Hu ZHOU, Rui TANG, Haining FAN, Qian LU. Research advances in immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(5): 1197-1203. doi: 10.3969/j.issn.1001-5256.2023.05.031
[6]	Pengwei REN, Ying HAN, Xinmin ZHOU. Predictive indicators for the efficacy of targeted therapy/immunotherapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2705-2709. doi: 10.3969/j.issn.1001-5256.2023.11.028
[7]	Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG. Research advances in immune checkpoint inhibitor-related cholangitis[J]. Journal of Clinical Hepatology, 2023, 39(2): 463-468. doi: 10.3969/j.issn.1001-5256.2023.02.034
[8]	Jin LEI, Linzhi ZHANG, Yinying LU, Bowen CHEN, Shi ZUO. Local embolization combined with targeted comprehensive immunotherapy in treatment of sarcomatoid hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2022, 38(4): 880-882. doi: 10.3969/j.issn.1001-5256.2022.04.026
[9]	Kangwei LI, Ding WEI, Ruohan ZHANG, Xiao LI, Kaishan TAO. Application of chimeric antigen receptor T-cell immunotherapy in primary liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(10): 2387-2390. doi: 10.3969/j.issn.1001-5256.2022.10.036
[10]	Hanping WANG. Adverse reactions associated with immune checkpoint inhibitor in treatment of liver cancer and related treatment measures[J]. Journal of Clinical Hepatology, 2022, 38(5): 985-991. doi: 10.3969/j.issn.1001-5256.2022.05.003
[11]	Guoming SHI, Yanzhi PEI, Pinxiang LU, Jun CAO, Jian ZHOU, Jia FAN. Immune checkpoint inhibitors for treatment of biliary malignant tumors[J]. Journal of Clinical Hepatology, 2022, 38(5): 998-1001. doi: 10.3969/j.issn.1001-5256.2022.05.005
[12]	Xiufeng LIU, Jue ZHANG, Lin YAO, Chaoxu YANG. Advances in targeted therapy combined with immunotherapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 992-997. doi: 10.3969/j.issn.1001-5256.2022.05.004
[13]	Dan LIU, Tiantian YAO, Yuhan ZHANG, Guiqiang WANG, Yan WANG. Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review[J]. Journal of Clinical Hepatology, 2022, 38(11): 2457-2461. doi: 10.3969/j.issn.1001-5256.2022.11.005
[14]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[15]	Jingzhong OUYANG, Yanzhao ZHOU, Ruili ZHU, Zhengzheng WANG, Xun CHEN, Jinxue ZHOU, Qingjun LI. Application of combined therapy with molecular-targeted drugs and immune checkpoint inhibitors and other combined therapies in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 925-930. doi: 10.3969/j.issn.1001-5256.2021.04.043
[16]	Zhaoyue WANG, Lai WEI, Yuan HUANG. Advances in the application of programmed death-1/programmed death-ligand 1 inhibitors in the treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 437-443. doi: 10.3969/j.issn.1001-5256.2021.02.040
[17]	Sun Tao, Ren YanQiao, Cao YanYan, Zheng ChuanSheng. Advances in immune checkpoint inhibitor combined with other treatment methods for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(6): 1386-1388. doi: 10.3969/j.issn.1001-5256.2020.06.043
[18]	Wei JianYing, Sun Wei, Liu XiaoMin, Chen JingLong. Advances in targeted therapy and immunotherapy for hepatocelluar carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(10): 2320-2324. doi: 10.3969/j.issn.1001-5256.2020.10.035
[19]	Luo Kui, Sun Hang, Wu ChuanXin. Immunotherapy for biliary tract cancer: Current status and perspectives[J]. Journal of Clinical Hepatology, 2019, 35(12): 2837-2840. doi: 10.3969/j.issn.1001-5256.2019.12.043

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (753) PDF downloads(76)

Establishment of a noninvasive predictive model for antiviral therapy in patients with chronic hepatitis B virus infection and an age of ≤30 years

DOI: 10.12449/JCH240708

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Establishment of a noninvasive predictive model for antiviral therapy in patients with chronic hepatitis B virus infection and an age of ≤30 years

DOI: 10.12449/JCH240708

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content